PDS Biotechnology Corp. released an overview of its oncology drug development programs, PDS0301 (formerly PDS01ADC and NHS-IL12) and PDS0101 (Versamune HPV). The filing details forward-looking statements regarding risks to these operations including reliance on additional financing, threats to intellectual property, and uncertainties in clinical trial results.